ICU Medical returns to quarterly profit as sales climb and margins widen
The infusion-therapy maker posted higher sales and a sharply better gross margin for the September quarter, and says full-year earnings should land near the top of its range.
ICU Medical (Nasdaq: ICUI) closed its September quarter with sales of $560.4M, up from $537.0M a year earlier, an increase of roughly $23M. The company announced the figures on 5 November.
The more notable shift came further down the income statement. ICU Medical booked GAAP net income of $26.8M for the three months to 30 September 2026, against a net loss in the same period of 2025. Gross margin rose to 42% from 37%, a five-point gain.
Management left its 2026 outlook in place, including adjusted EBITDA of $415M-$435M, and said it now expects to finish toward the upper end of that range.
The original earnings release was not available to CompePharma, so this report does not cover segment performance, product-line trends or what drove the margin improvement. The information on file also says nothing about any change in product supply or quality status.
Why it matters
- Reaffirmed guidance, with a lean toward the high end of the adjusted EBITDA range, gives partners and investors a firmer view of full-year earnings.
- A five-point gross margin gain and a swing to GAAP profit are financial indicators only; the sources do not say whether they reflect pricing, mix or cost changes.
- Readers needing segment or operational detail should consult the company's full earnings release and filings.
Company's press release (SEC filing): Icu Medical Inc/De ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
